Effects of SGLT2 Inhibitor on Markers of Inflammation, Atherosclerosis and Left Ventricular Strain in Diabetic Patients With Coronary Artery Disease
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Coronary artery disease; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 07 Jan 2020 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified January 2018).
- 15 Jan 2018 New trial record